Abstract
Laronidase (Aldurazyme) is the primary enzyme replacement therapy (ERT) for Mucopolysaccharidosis type I (MPS I). While its efficacy is well-documented, clinical trials for rare diseases often lack the scale and duration to capture long-term or rare adverse events (AEs). This study utilizes over 20 years of data from the FDA Adverse Event Reporting System (FAERS) to provide a comprehensive real-world safety profile, identifying both expected side effects and significant new safety signals.
Introduction
MPS I is a rare lysosomal storage disorder characterized by a deficiency in the enzyme required to break down glycosaminoglycans (GAGs), leading to progressive multi-organ damage. Since its approval in 2003, laronidase has significantly improved patient outcomes. However, a "safety gap" exists due to the limitations of pre-marketing clinical trials. This research addresses this gap through post-marketing surveillance, aiming to identify rare or delayed AEs that warrant clinical attention.
Methodology
The researchers conducted a retrospective disproportionality analysis using the FAERS database, covering reports from Q1 2004 through Q4 2024. The study focused on cases where laronidase was identified as the "primary suspect" (PS) drug.
To ensure statistical robustness, four algorithms were employed: Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR) for high sensitivity, and Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-item Gamma Poisson Shrinker (MGPS) for high specificity. Additionally, a Time-to-Onset (TTO) analysis was performed to understand the temporal distribution of AEs.
Results
The final dataset comprised 3,677 unique adverse event reports. A critical finding was the temporal delay in AE emergence: 64.06% of events occurred more than 360 days after the initiation of treatment, highlighting the necessity for long-term monitoring.
Analysis at the System Organ Class (SOC) level revealed significant signals across several physiological systems, with infections and respiratory disorders showing the highest reporting odds.
Common and Expected Adverse Events
The most frequently reported AEs included pyrexia (n=465), pneumonia (n=223), and cough (n=167). These findings align with the known immunogenic profile of ERT, where over 90% of patients develop anti-drug antibodies (ADA) that can trigger hypersensitivity reactions.
Unexpected Safety Signals
The study uncovered several significant signals not currently listed on the drug's label:
- Neurological Risks: Strong signals were detected for hydrocephalus (ROR = 50.47) and seizures (ROR = 3.1).
- Ocular Complications: Unexpected risks for blindness (n=44, ROR=5.02) and glaucoma (n=32, ROR=7.56) were identified, suggesting potential limitations in enzyme penetration into ocular tissues.
Discussion and Conclusion
This real-world analysis confirms the known safety profile of laronidase while surfacing critical new concerns regarding neurological and ocular health. The high incidence of late-onset AEs suggests that safety management for MPS I patients must extend well beyond the initial infusion phase.
While the FAERS database has inherent limitations—such as voluntary reporting bias and potential confounding by the underlying disease—the statistical strength of these new signals warrants further prospective clinical investigation. Clinicians should maintain heightened vigilance for neurological and ocular symptoms in patients receiving long-term laronidase therapy.
Summary updated